JP2018532804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532804A5 JP2018532804A5 JP2018543040A JP2018543040A JP2018532804A5 JP 2018532804 A5 JP2018532804 A5 JP 2018532804A5 JP 2018543040 A JP2018543040 A JP 2018543040A JP 2018543040 A JP2018543040 A JP 2018543040A JP 2018532804 A5 JP2018532804 A5 JP 2018532804A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- uveitis
- antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010046851 Uveitis Diseases 0.000 claims 6
- 239000003246 corticosteroid Substances 0.000 claims 6
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 4
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 4
- 208000001344 Macular Edema Diseases 0.000 claims 4
- 206010025415 Macular oedema Diseases 0.000 claims 4
- 201000010230 macular retinal edema Diseases 0.000 claims 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 4
- 229960004618 prednisone Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021147378A JP2021193120A (ja) | 2015-11-03 | 2021-09-10 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2023021270A JP7581399B2 (ja) | 2015-11-03 | 2023-02-15 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2024189424A JP2025020227A (ja) | 2015-11-03 | 2024-10-29 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250269P | 2015-11-03 | 2015-11-03 | |
| US62/250,269 | 2015-11-03 | ||
| EP16306166 | 2016-09-14 | ||
| EP16306166.6 | 2016-09-14 | ||
| US201662408391P | 2016-10-14 | 2016-10-14 | |
| US62/408,391 | 2016-10-14 | ||
| PCT/US2016/060344 WO2017079443A1 (en) | 2015-11-03 | 2016-11-03 | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147378A Division JP2021193120A (ja) | 2015-11-03 | 2021-09-10 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532804A JP2018532804A (ja) | 2018-11-08 |
| JP2018532804A5 true JP2018532804A5 (cg-RX-API-DMAC7.html) | 2019-12-05 |
| JP7272794B2 JP7272794B2 (ja) | 2023-05-12 |
Family
ID=57018106
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543040A Active JP7272794B2 (ja) | 2015-11-03 | 2016-11-03 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2021147378A Pending JP2021193120A (ja) | 2015-11-03 | 2021-09-10 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2023021270A Active JP7581399B2 (ja) | 2015-11-03 | 2023-02-15 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2024189424A Pending JP2025020227A (ja) | 2015-11-03 | 2024-10-29 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147378A Pending JP2021193120A (ja) | 2015-11-03 | 2021-09-10 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2023021270A Active JP7581399B2 (ja) | 2015-11-03 | 2023-02-15 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
| JP2024189424A Pending JP2025020227A (ja) | 2015-11-03 | 2024-10-29 | ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10968278B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3371224A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7272794B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180073680A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108473583A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016348418B8 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018008900A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3003874A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL319993A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2018005589A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201803654TA (cg-RX-API-DMAC7.html) |
| TW (3) | TWI729022B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017079443A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| CA3003874A1 (en) | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
| JP7504871B2 (ja) | 2018-08-29 | 2024-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 関節リウマチを有する対象を治療するための方法および組成物 |
| KR20210122810A (ko) | 2019-01-31 | 2021-10-12 | 사노피 바이오테크놀로지 | 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체 |
| EP3959240A1 (en) | 2019-04-24 | 2022-03-02 | Sanofi Biotechnology | Methods of diagnosis and treatment of rheumatoid arthritis |
| AU2020288561A1 (en) | 2019-06-04 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| JP2022537555A (ja) | 2019-06-20 | 2022-08-26 | 武田薬品工業株式会社 | ウイルスベースの遺伝子療法による治療方法 |
| AR123948A1 (es) * | 2020-10-28 | 2023-01-25 | Regenxbio Inc | ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES |
| CA3264497A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Predicting response to il-6 antagonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU218140B (hu) | 1991-04-25 | 2000-06-28 | Chugai Seiyaku Kabushiki Kaisha | Humán interleukin-6-receptorral szembeni átalakított humán antitest |
| ES2384222T3 (es) | 1994-10-07 | 2012-07-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo |
| UA66757C2 (en) | 1996-02-26 | 2004-06-15 | Advanced Res & Tech Inst | Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| EP1751612B1 (en) | 2004-05-06 | 2009-02-25 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for the treatment of uveitis |
| US8080248B2 (en) * | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| CN102089326B (zh) * | 2008-05-13 | 2014-12-31 | 诺维莫尼公司 | 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法 |
| CN102883748A (zh) | 2010-05-07 | 2013-01-16 | 爱克索马技术有限公司 | 治疗IL-1β相关状况的方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| BR112015010360A8 (pt) * | 2012-11-08 | 2018-01-16 | Eleven Biotherapeutics Inc | antagonistas de il-6 e utilização dos mesmos. |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| JP6657089B2 (ja) | 2013-11-22 | 2020-03-04 | サノフィ・バイオテクノロジー | 関節リウマチを治療するための組成物およびこれを使用する方法 |
| IL295414B1 (en) | 2014-03-27 | 2025-10-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| CA3003874A1 (en) * | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
-
2016
- 2016-11-03 CA CA3003874A patent/CA3003874A1/en active Pending
- 2016-11-03 JP JP2018543040A patent/JP7272794B2/ja active Active
- 2016-11-03 MX MX2018005589A patent/MX2018005589A/es unknown
- 2016-11-03 WO PCT/US2016/060344 patent/WO2017079443A1/en not_active Ceased
- 2016-11-03 US US15/342,833 patent/US10968278B2/en active Active
- 2016-11-03 TW TW105135684A patent/TWI729022B/zh active
- 2016-11-03 KR KR1020187015533A patent/KR20180073680A/ko active Pending
- 2016-11-03 TW TW110117779A patent/TWI786636B/zh active
- 2016-11-03 SG SG11201803654TA patent/SG11201803654TA/en unknown
- 2016-11-03 AU AU2016348418A patent/AU2016348418B8/en active Active
- 2016-11-03 TW TW111143328A patent/TW202339795A/zh unknown
- 2016-11-03 IL IL319993A patent/IL319993A/en unknown
- 2016-11-03 EP EP16810513.8A patent/EP3371224A1/en active Pending
- 2016-11-03 BR BR112018008900A patent/BR112018008900A8/pt not_active Application Discontinuation
- 2016-11-03 CN CN201680077216.5A patent/CN108473583A/zh active Pending
-
2018
- 2018-05-03 MX MX2022011972A patent/MX2022011972A/es unknown
-
2021
- 2021-02-24 US US17/183,904 patent/US20210301027A1/en active Pending
- 2021-09-10 JP JP2021147378A patent/JP2021193120A/ja active Pending
-
2023
- 2023-02-15 JP JP2023021270A patent/JP7581399B2/ja active Active
- 2023-09-20 AU AU2023233110A patent/AU2023233110A1/en active Pending
-
2024
- 2024-10-29 JP JP2024189424A patent/JP2025020227A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532804A5 (cg-RX-API-DMAC7.html) | ||
| PE20191758A1 (es) | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares | |
| WO2008154251A4 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| JP2017503820A5 (cg-RX-API-DMAC7.html) | ||
| JP2012165745A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530226A5 (cg-RX-API-DMAC7.html) | ||
| JP2014240408A5 (cg-RX-API-DMAC7.html) | ||
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| JP2018507220A5 (cg-RX-API-DMAC7.html) | ||
| AR066660A1 (es) | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento | |
| Polanco et al. | Everolimus-based immunosuppression therapy for BK virus nephropathy | |
| Calonge | Classification of ocular atopic/allergic disorders and conditions: an unsolved problem | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| WO2019067405A3 (en) | Ketogenic diet compatible fenfluramine formulation | |
| JP2015131856A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502198A5 (cg-RX-API-DMAC7.html) | ||
| Molina et al. | Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis | |
| JP2017502023A5 (cg-RX-API-DMAC7.html) | ||
| WO2017079443A8 (en) | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same | |
| JP2018530574A5 (cg-RX-API-DMAC7.html) | ||
| JP2017520562A5 (cg-RX-API-DMAC7.html) | ||
| AR069233A1 (es) | Anticuerpos anti- factor b y sus usos | |
| Brown et al. | Boston keratoprosthesis type 1 for herpes simplex and herpes zoster keratopathy | |
| Donoso et al. | Comparative study of keratoconus between Anwar's deep anterior lamellar keratoplasty versus converted penetrating keratoplasty | |
| Menezo et al. | Clinical outcome of chronic immunosuppression in patients with non‐infectious uveitis |